PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.
体外研究
PHA 568487 increases anti-oxidant gene expression and decreases oxidative stress and phosphorylation of NF-κb p65. Methyllycaconitine (MLA) has the opposite effects.
PHA increases anti-oxidant genes and NADPH oxidase expression associated with decreased phosphorylation of NF-kB p65 in microglia/macrophages.
体内研究
PHA 568487 attenuates neuronal injury and behavioral dysfunction in mice with ischemic stroke only and ischemic stroke plus tibia fracture.
PHA 568487 (1.25 mg/kg; i.p.; treated daily)-treated ischemic rats shows a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.
Animal Model:
C57BL/6J male mice (10-12 weeks old)
Dosage:
PHA 568487 (PHA; 0.4 and 0.8 mg/kg); Methyllycaconitine (MLA; 4 and 6 mg/kg)
Administration:
Injected intraperitoneally once on day 1, or twice on days 1 and 2, after pMCAO
Result:
Injection of PHA (0.8 mg/kg) and MLA (6 mg/kg) on days 1 and 2 after pMCAO yielded the best effect on infarct volume and behavior tests.
Animal Model:
Adult male Sprague-Dawley rats (297 6±8.3 g)
Dosage:
1.25 mg/kg
Administration:
I.p.;0.1 mL; treated daily
Result:
Showed a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.
分子式
C20H24N2O7
分子量
404.41
CAS号
527680-57-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.